EPTS OpenMRS

Reports Requirements
Indicator Specification Document
Early Retention Monitoring – 4 months (61 and 120 days) Indicator

Version 1.3

Version

Date	Version	Description	Author(s)
January 30, 2019	1.0	Initial creation of document	Ketmia Matavele
February 6, 2019	1.1	FGH updates incorporated. Additional disaggregation added.	Pinki Meggi
February 8, 2019	1.2	Updated cohort period.	Pinki Meggi
February 11, 2019	1.3	CDC updates incorporated: Renamed back IM-ER4 and 4 months in definition of disaggregation. Updated typo in cohort period. Updated age definition to be more specific in terms of intervals.	Pinki Meggi

Approvals and Sign-off

Approvals Panel

Version	Approver	Approved by	Date
1.3	CDC		

Approvals Panel

The Approver signatures signify that this document has been reviewed and satisfies the project governance, business and system needs.

Document Title: EPTS OpenMRS Indicator Specification and Requirements – ERM-4 months

Year: 2019

Authors Signature

Version	Authors	Approved by	Date
1.3	FGH		
	Jembi HS		

Authors

The Authors signatures represent the EPTS Requirements Gathering Group composed by two CDC Partners, Jembi Health Systems (HIS Partner) and FGH (Clinical Partner) and signify that this document is complete and that, to the best of their knowledge, it adequately addresses the document's intended purpose and scope and it is accurate.

Table of Contents

I Introduction

I.a Purpose

The purpose of this document is to capture the requirements and specifications for the **Early Retention Monitoring (ERM) 3 months retention** Indicator. This indicator is reported from the EPTS OpenMRS system in use by the PEPFAR Clinical partners to capture patient level data in retrospective mode at the health facilities.

I.b Scope and Key Assumptions

This document defines the functional and technical requirements to generate the indicator in an OpenMRS Report.

The key Assumptions are:
All patients captured in the OpenMRS system are HIV positive.
All patients captured in the OpenMRS system have been on antiretroviral therapy (ART) at some time.

I.c References

Not defined.

II. Indicator Definition

II.a Description

IM-ER4 (3 months retention) indicator reports the number and percentage of adults and children newly enrolled on antiretroviral therapy (ART) 4 months prior to the reporting period end date who have either a clinical consultation or an ART pick-up between 61 and 120 days after ART initiation date.

II.b Numerator and Denominator

IM_ER4 (3 months retention) indicator **denominator** is the number of patients newly initiating ART 4 months prior to the reporting period end date (one month cohort enrollment period). For Example, for the reporting period of April (end date is April 20th, 2019), the one-month cohort period includes patients who initiated ART from November 21st, 2018 to December 20th 2018.

3 mo retention on ART		
Cohort enrollment period		
Cohort enrollment start date (DD/MM/ AAAA)	**Cohort enrollment end date (DD/MM/ AAAA)**	**Reporting Period end date (DD/MM/AAAA)**
21/11/2018	20/12/2018	20/04/2019

IM-ER4 (3 months-retention) indicator **numerator** is the number of patients newly initiating ART 4 months prior to the reporting end date who have either a clinical consultation or an ART pick-up between 61 and 120 days after ART initiation date.

II.c Indicator Reporting Level and Frequency

Not applicable

II.d Indicator Primary Sources

The IM-ER4 (3 months-retention) indicator should be collected from:

- Facility ART registers/databases
- Program monitoring tools
- Drug supply management systems (Pharmacy)

II.e Population

IM-ER4 months **denominator** populations **includes**:

- Patients (adults and children) who initiated treatment (newly enrolled in ART) 4 months prior to the reporting end date.

IM-ER4 (3 months-retention) **numerator** population **includes:**

- Patients (adults and children) who initiated treatment (newly enrolled in ART) 4 months prior to the reporting end date and who have either a clinical consultation or an ART pick-up between 61 and 120 days after ART initiation date.

IM-ER4 (3 months-retention) **denominator** and **numerator** population **excludes**:

- Patients known to transfer in from another facility;

II.f Disaggregation

The IM-ER4 Indicator should be reported by the following disaggregation:

- First Level: All Patients, Pregnant Women, Breastfeeding Women, Children (0-14, excluding pregnant and breastfeeding women), Adults (15+, excluding pregnant and breastfeeding women)

- Second Level (for all first level population): Initiated ART, Alive & not transferred-out and In Treatment, Dead, Lost to Follow up (LTFU), Transferred-out, Stopped/Suspended.

    - Initiated ART: patients who initiated treatment 4 months prior to the reporting end date excluding transferred-in patients.

    - Alive & not Transferred out and In Treatment: patients who initiated treatment 4 months prior to the reporting end date excluding transferred-in patients, who returned for consultation or drugs pick up, between 61 and 120 days after ART initiation, and who are not dead or transferred out patient by end of reporting period.

    - Alive & not Transferred out and NOT In Treatment: patients who initiated treatment 4 months prior to the reporting end date excluding transferred-in patients, who DID NOT return for consultation or drugs pick up, between 61 and 120 days after ART initiation, and who are not dead or transferred out patient by end of reporting period.

    - Dead: patients who initiated ART 4 months prior to the reporting end date excluding transferred-in patients, and who are registered as “dead” by end of reporting period.

- LTFU: patients who initiated ART 4 months prior to the reporting end date excluding transferred-in patients, and who from the next scheduled drugs-pick up or consultation date have not returned within 60 days.

- Transferred out: patients who initiated ART 4 months prior to the reporting end date excluding transferred-in patients and who are registered as “transferred-out” by end of reporting period.

- Stopped treatment: patients who initiated ART 4 months prior to the reporting end date excluding transferred-in patients and who are registered as “stopped/suspended treatment” by end of reporting period.

- % Retention (Alive & not Transferred out and In Treatment / Initiated ART minus Transferred Out): calculated field based on “IIg. Formula”.

- Note: age is defined as the age of the patient at the date of initiation on ART, not the age at the date of reporting.

II.g How to calculate Retention

The formula to calculate three months retention is the following:

NUMERATOR / (DENOMINATOR minus Transferred-out)

- NUMERATOR = Alive & not Transferred out and In Treatment: patients who initiated treatment 4 months prior to the reporting end date, excluding transferred-in patients, who returned for consultation or drugs pick up, between 61 and 120 days after ART initiation, who are not dead or transferred out patient.
- DENOMINATOR = Initiated ART: patients who initiated treatment 5 months prior to the reporting end date excluding transferred-in patients.
- Transferred-out: patients who initiated ART 5 months prior to the reporting end date excluding transferred-in patients and who are registered as “transferred-out” during the reporting period.

II.h Report Output

The report output for IM_ER4 (3 months retention) indicator can be found as attachment

III. Requirements Definition

III.a Key Assumptions

The key assumptions for **IM-ER4 (3 months retention**) indicator and related to EPTS OpenMRS are the following:

1. All patients captured in the OpenMRS system are HIV positive.
2. All patients captured in the OpenMRS system have initiated antiretroviral therapy (ART) at some time.
3. All patients captured in the OpenMRS doesn't include the PEP (Post exposure prophylaxis) patients.
4. The primary sources for **IM-ER4** are "FILA" (Annex 1), "Ficha de Seguimento do Adulto"(Annex 2), "Ficha de Seguimento de Pediatria (Annex 3).
5. The patients in ART program are enrolled in SERVICO TARV-TRATAMENTO;
6. All patients must be officially enrolled on ART Service at end of reporting period on specified health facility. (officially enrolment mean 1) have "Processo Clinico Parte A" registered in health facility or 2) has been enrolled in "SERVICO TARV – CUIDADO" program in health facility or
   3) has been enrolled in "SERVICO TARV – TRATAMENTO" as "Transferred in" in health facility, TO BE EXCLUDED.

IV.b List of Functional Requirements

Requirement #	**Category/ Functional Area**	**Requirement**
IM-ER4_FR1	Reports	The system will generate the IM-ER4 indicator report for selected reporting period (start and end date) and specific location (health facility).
IM-ER4_FR2	Indicator Denominator	The system will generate IM-ER4 indicator **Denominator** as number of patients (adult and children) newly enrolled on ART 4 months prior the reporting period end date with the specified disaggregation. The patients included are the patients who initiated treatment 4 months prior to the reporting period end date (one-month enrollment cohort) The system will exclude the following patients: ● Patients who were transferred in from another facility;
IM-ER4_FR3	Indicator numerator	The system will generate IM-ER4 months (3 months retention) indicator **numerator** as number of patients (adult and children) newly enrolled on ART 4 months prior to the reporting period end

		date who have either a clinical consultation or an ART pick-up between 61 and 120 days after ART initiation date. The patients included are the patients who initiated the treatment 4 months prior to the reporting period end date who have either a clinical consultation or an ART pick-up between 61 and 120 days after ART initiation date. The system will **exclude** the following patients: ● Patients who were transferred in from another facility ● Patients who are transferred out by the end of the reporting period ● Patients who are dead by the end of the reporting period
IM-ER4_FR4	Indicator Disaggregation Denominator	The system will generate the IM-ER4 months indicator with following disaggregation: ● First Level Population Disaggregation: ○ All patients ○ Pregnant women ○ Breastfeeding women ○ Children (0-14, excluding pregnant and breastfeeding women) ○ Adults (15+, excluding pregnant and breastfeeding women) ● Second Level Disaggregation for each First Level Population ○ Initiated ART: denominator (**IM-ER4_FR2)** ○ Alive & Not Transferred Out and NOT in Treatment: patients who Initiated ART (denominator) and who DID NOT return for consultation or drugs pick up, between 61 and 120 days after ART initiation, excluding dead and transferred out patients by end of reporting period: numerator (**IM-ER4_FR3)** ○ Dead: patients who Initiated ART (denominator) and are registered as “dead” by end of reporting period. ○ Lost to Follow Up: patients who initiated ART(denominator) and from the next scheduled drugs-pick up or consultation date have not returned within 60 days. ○ Transferred out: patients who Initiated ART (denominator) and are registered as “transferred-out” by end of reporting period. ○ Stopped treatment: patients who Initiated ART (denominator) and are registered as “stopped/suspended” by end of reporting period.

		○ % Retention: Numerator (Alive & not Transferred out and In Treatment and who returned for consultation or drugs pick up, between 61 and 120 days after ART initiation)/ Denominator (Initiated ART) minus Transferred- out).
IM-ER4_FR5	Indicator Disaggregation Numerator	The system will generate the IM_ER4 indicator **numerator** with the following disaggregation: • First Level Population Disaggregation: ○ All patients, ○ Pregnant Women ○ Breastfeeding Women ○ Children (0-14, excluding pregnant and breastfeeding women) ○ Adults (15+, excluding pregnant and breastfeeding women)
IM-ER4_FR6	Patient who initiated treatment	The system will identify patients who **initiated the treatment** as following: ● All patients who have their first drugs pick up date set in Pharmacy form (*FILA*) during the cohort period. ● All patients who have initiated the drugs (ARV PLAN = START DRUGS) during the pharmacy or clinical visits during the cohort period ● All patients who has the first historical start drugs date set during the cohort period in Pharmacy Tool (FILA) or Clinical tools (*Ficha de Seguimento Adulto and Ficha de Seguimento Pediatria*). ● All patients enrolled in ART Program during the cohort period; ● Ensure that the ART start date is truly the first occurrence in the cohort period. This is to guard against situations of patients that for some reason have more than one ART start date registered in the system
IM-ER4_FR7	Patients who have been transferred in – **to be excluded**	The system will identify patients who **have been transferred in** as following: ● All patients who are enrolled in ARV Program (*Serviço TARV- Tratamento*) and have as state of patient "*Transfer From other facility"* in the patient chart.
IM_ER4_FR8	Patients disaggregation - Dead	The system will identify patients who are **Dead** as following : ● All patients who are enrolled in Program (Servico TARV-TRATAMENTO) and have patient state = *Died* and patient Died state start date is before the reporting end date.
IM_ER4_FR9	Patients disaggregation - Transferred Out	The system will identify patients who are **Transferred-out** as following : ● All patients who are enrolled in Program (Servico TARV-TRATAMENTO) and have patient state = *Transferred out to another health facility* and patient state start date is

		before the reporting end date.
IM_ER4_FR10	Patients disaggregation - Suspended/Stopped treatment	The system will identify patients who are **Suspended/Stopped Treatment** as following : ● All patients who are enrolled in Program (Servico TARV-TRATAMENTO) and have patient state = *Stopped/suspended the treatment* and patient state start date is before the reporting end date.
IM-ER4_FR11	Patients disaggregation - Lost To Follow-up	The system will identify patients who are **LTFU** as following ● Patient on ART who have the next scheduled drugs- pick up date and have not returned within 60 days; or ● Patient on ART who have the next scheduled consultation date and have not returned within 60 days.
IM-ER4_FR12	Patients disaggregation - pregnant	The system will identify women patients who are **pregnant** as following: ● Patients that are female and were marked as “PREGNANT” in the initial consultation or follow-up consultation by end of reporting period or ● Patients that are female and have “Number of weeks Pregnant” registered in the initial or follow-up consultation by end of reporting period or ● Patients that are female and have “Pregnancy Due Date” registered in the initial or follow-up consultation by end of reporting period or ● Patients that are female and enrolled on PTV/ETC program by end of reporting period.
IM-ER4_FR13	Patients Disaggregation - Breastfeeding	The system will identify women patients who are breastfeeding as following: All patients that are female and ● have the “Delivery date” registered in the initial or follow-up consultations and where the delivery date by end of reporting period. ● have started ART for being breastfeeding as specified in “CRITÉRIO PARA INÍCIO DE TARV” in the initial or follow-up consultations that occurred by end of reporting period. ● have registered as breastfeeding in follow up consultation by end of reporting period. ● Excluding patients that are pregnant
IM-ER4_FR14	Patients Disaggregation- Children and Adults	The system will identify patients age for children and adults disaggregation as following: ● Patients with birth date information registered in the system should be calculated the age of the patient at the date of initiation on ART (birth date minus ART initiation date). ● Children will be considered as 0 to 14 years old, excluding pregnant and breastfeeding women. ● Adults will be considered as equal or more than 15 years

		old, excluding pregnant and breastfeeding women.
IM-ER4_FR15	Reporting Period and Cohort Period	The user will enter as input parameters the “reporting start date” and “reporting end date”. The **“cohort start date”** will be defined as 5 months prior plus 1 day of reporting end date (end date – 5 months + 1 day). The **“cohort end date”** will be defined as 4 months prior of submitted reporting end date (end date – 4 months).

IV. Testing Scenarios

Not defined.

V. Technical Specifications

V.a Pseudo-code

Not defined

V.b Data fields and elements

- Define the data element(s) used to determine the reporting range
  The reporting range dates will be specified by user before submitting the report request as “startDate”, “endDate”.

- Define the data element(s) used to determine if a patient is newly enrolled in ART

	Encounter Type	Data Element(s)	Data Element Value
Patients on ART who initiated the ARV DRUGS	S.TARV: ADULTO SEGUIMENTO (ID=6) S.TARV: PEDIATRIA SEGUIMENTO(ID=9) S.TARV: FARMACIA (ID=18)	ARV PLAN (OBS CONCEPT ID = 1255)	START DRUGS (OBS Value Code =1256)
		MINIMUM Encounter DATE (encounter. encounter_datetime)	>=startDate and <= endDate
Patients on ART who picked up drugs in first visit	S.TARV: ADULTO SEGUIMENTO (ID=6) S.TARV: PEDIATRIA SEGUIMENTO(ID=9) S.TARV: FARMACIA (ID=18)	MINIMUM HISTORICAL START DATE (OBS CONCEPT ID 1190)	>=startDate and <= endDate
Patients enrolled in ART Program	----	Patient PROGRAM (patient_program. program_id)	SERVICO TARV - TRATAMENTO (program_id =2)
		Program Enrolment Date (patient_program. Date_enrolled)	>=startDate and <= endDate
Patients with first drugs pick up date set in Pharmacy	S.TARV: FARMACIA (ID=18)	MINIMUM Encounter DATE (encounter. encounter_datetime)	>=startDate and <= endDate

- Define the data elements used to identify the patient’s age: *patient.birthdate*

- Define the data elements used to identify is a patient is breastfeeding

	Encounter Type	Data Element(s)	Data Element Value
Patients that are female and have the “Delivery date” (obs concept id 5599)	S.TARV: ADULTO INITIAL CONSULTATION (ID=5)	Delivery Date (OBS CONCEPT ID = 5599)	Date (OBS value_time)>= startDate and <=endDate

registered in the initial or follow-up consultation where delivery date is between start and end date.	S.TARV: ADULTO SEGUIMENTO (ID=6)		
Patients that are female and have registered as breastfeeding in follow up consultation between start and end date (encounter datetime).	S.TARV: ADULTO SEGUIMENTO (ID=6)	BREASTFEEDING (CONCEPT ID 6332)	OBS Value Code =1065
		Encounter DATE (encounter. encounter_datetime)	>=startDate, <= endDate
Patients that are female and have started ART for being breastfeeding as specified in “CRITÉRIO PARA INICIO DE TRATAMENTO ARV” with response equal to “LACTACAO” in the initial or follow-up consultation between start & end date	S.TARV: ADULTO INITIAL CONSULTATION (ID=5) S.TARV: ADULTO SEGUIMENTO (ID=6)	“CRITÉRIO PARA INICIO DE TRATAMENTO ARV” (OBS CONCEPT ID = 6334)	LACTACAO (OBS Value Code = 6332)
		Encounter DATE (encounter. encounter_datetime)	>=startDate, <= endDate
Patients enrolled in PTV(ETV) Program	----	Patient PROGRAM (patient_program. program_id)	PTV (program_id =8)
		Patient Program State Date (patient state id= 27 and start_date)	>=startDate and <= endDate

- Define the data elements used to identify if a patient has transferred in

	Encounter Type	**Data Element(s)**	**Data Element Value**
Patient on ART who was transferred in from other facility	S.TARV: ADULTO SEGUIMENTO (ID=6) S.TARV: PEDIATRIA SEGUIMENTO(ID=9) S.TARV: FARMACIA (ID=18)	ARV PLAN (OBS CONCEPT ID = 1255)	TRANSFERRED FROM OTHER FACILITY (OBS Value Code =29)
		Encounter DATE (encounter. encounter_datetime)	>= startDate and <= endDate
Patients enrolled in SERVICO TARV TRATAMENTO Program	----	Patient PROGRAM (patient_program. program_id)	SERVICO TARV TRATAMENTO (program_id =2)
		Patient Program State Date (patient state id= 29	>=startDate and <= endDate

		and start_date)	

- Define the data elements used to identify if a patient has reinitiated the treatment:
-

	Encounter Type	**Data Element(s)**	**Data Element Value**
Patient on ART who has reinitiated the treatment	S.TARV: ADULTO SEGUIMENTO (ID=6) S.TARV: PEDIATRIA SEGUIMENTO(ID=9)	ARV PLAN (OBS CONCEPT ID = 1255)	RESTART (OBS Value Code =1705)
		Encounter DATE (encounter. encounter_datetime)	>= startDate and <= endDate

- Define the data elements used to identify if a patient has Dead:
  - *Patient_program.program_id =2 = SERVICO TARV-TRATAMENTO*
  - *Patient_State.state = 10 = DIED*
  - *Patient_State.start_date <= endDate*
  - *Patient_state.end_date is null*
- Define the data elements used to identify if a patient has Transferred-out:
  - *Patient_program.program_id =2 = SERVICO TARV-TRATAMENTO*
  - *Patient_State.state = 7 = Transferred out to another health facility*
  - *Patient_State.start_date <= endDate*
  - *Patient_state.end_date is null*
- Define the data elements used to identify if a patient has stopped/suspend:
  - *Patient_program.program_id =2 = SERVICO TARV-TRATAMENTO*
  - *Patient_State.state = 8 = Stopped/suspended the treatment*
  - *Patient_State.start_date <= endDate*
  - *Patient_state.end_date is null*

VI. ANNEXES

Annex 1- OpenMRS EPTS FILA



Annex 2- OpenMRS EPTS Adulto Seguimento



OpenMRS

Página Inicial | Procurar/Registar Paciente | Dicionário | Cohort Builder | Reporting | Administração

Maria Carlos | ADULTO: SEGUIMENTO (S.TARV: ADULTO SEGUIMENTO) | (Unsaved Form)

FICHA DE SEGUIMENTO PARA ADULTOS

REPÚBLICA DE MOÇAMBIQUE SERVIÇO NACIONAL DE SAÚDE Mod. SIS - H-10		Nome:Maria Carlos	
		Data de nascimento: 17/out/2018	Idade: 0- Sexo: F
NID: 01080805/17/00010	Nº do livro pré-TARV:	Página do livro pre-TARV:	Linha da Pág do pré-TARV:
	Nº do livro TARV:	Página do livro TARV:	Linha da Pág do TARV:

Data da Consulta	
Unidade Sanitária	Local Desconhecido
Médico	
Altura: (cm)[Última Altura:] Peso(kg):	
Indice de Massa Corporal (IMC):(kg/m2)	
Classificação Nutricional:	
Apoio Nutricional (ANJT)	S N Tipo: CSB Plumpy Nut Papa Enriquecida Outro
Temperatura (ºC):	
Tensão Arterial (TA)	/
Gravidez: Nova: DUM DPP:	PTV TARV
Lactante:	Sim Não

LABORATÓRIO

Data de Processamento do CD4 (d-m-a)	
CD4 (/mm) / CD4 (%)	/
Carga Viral (CV)	
G. Brancos (GB)	
Neutrofilos (N) (l/mm3 e %)	/
Linfócitos (L) (l/mm3 e %)	/
Hemoglobina (Hgb) (g/dl)	
Provas hepáticas - ALT / AST (U/L)	/
Glicémia (GL) (g/dl)	
Ureia (UR) (mg/dl) / Creatinina (CR) (mmol/L)	/
Amilase	
Teste de gravidez	Positivo Negativo
Plaquetas	
RPR	Positivo Negativo
ESTADIO OMS	Último Estadio []
Outros diagnósticos	Malária Anemia Malnutrição Leucemia Encefalopatia Otite Febre Sarcoma de Kaposi Diarreia Falência Terapeutica

Infecções Oportunistas

Rastreio de ITS(Tem sintomas sugestivas de ITS)?	Sim Não
Rastreio de TB(Tem sintomas sugestivas de TB)?	Sim Não
Resultado para a Investigação para TB de BK e/ou RX?	Positivo Negativo
Tratamento de TB (Veja Cartão de TB): Data Inicio: Data Fim:	Sim Não
Profilaxia com Cotrimoxazol - TPC: Data Inicio: Data Fim:	Sim Não
Profilaxia com INH - TPI: Data Inicio: Data Fim:	Sim Não
Aconselhado para Adesão aos Cuidados:	Sim Não

TARV:

Data de Elegibilidade para iniciar o TARV:	
Data de Inicio de TARV:	[15/dez/2018]
Critério de Elegibilidade para clínico do TARV:	
Data de Reinicio de TARV:	
Médicamentos ARVs	Esquema ARV: Tipo: Interrompeu por: Mudança de regime:
Outros Medicamentos	
Efeitos Secundarios do Tratamento	Anemia - A Neutropenia - N Pancreatite - P Hepatotoxicidade - H Alterações Psicológicas - AP Neuropatia Periférica - NP Miopatia - M Alergias Cutâneas - AC Lipodistrofia - L Acidose Láctica - AcL Diarreia - D Outros:
Aderente ao TARV:	Sim Não
Data da proxima consulta	
Data do proximo controlo de CD4:	
Referido para outro sector clinico:	
Referido para serviços comunitários:	
Observacoes:	



OpenMRS

Página Inicial | Procurar/Registar Paciente | Dicionário | Cohort Builder | Reporting | Administração

Maria Carlos | ADULTO: SEGUIMENTO (S.TARV: ADULTO SEGUIMENTO) | (Unsaved Form)

FICHA DE SEGUIMENTO PARA ADULTOS

REPÚBLICA DE MOÇAMBIQUE
SERVIÇO NACIONAL DE SAÚDE
Mod. SIS - H-10

Nome:Maria Carlos
Data de nascimento: 17/out/2018 | Idade: 0- Sexo: F

NID: 01080805/17/00010
Nº do livro pré-TARV: | Página do livro pre-TARV: | Linha da Pág do pré-TARV:
Nº do livro TARV: | Página do livro TARV: | Linha da Pág do TARV:

Data da Consulta
Unidade Sanitária: Local Desconhecido
Médico
Altura: [cm][Última Altura:]
Peso(kg)
Indice de Massa Corporal (IMC):(kg/m2)
Classificação Nutricional:
Apoio Nutricional (ANUT): S N Tipo: CSB Plumpy Nut Papa Enriquecida Outro
Temperatura (ºC):
Tensão Arterial (TA): /
Gravidez: Nova: DUM: DPP: PTV TARV
Lactante: Sim Não

LABORATÓRIO

Data de Processamento do CD4 (d-m-a)
CD4 (/mm) / CD4 (%) /
Carga Viral (CV)
G. Brancos (GB)
Neutrófilos (N) (/mm3 e %) /
Linfócitos (L) (/mm3 e %) /
Hemoglobina (Hgb) (g/dl)
Provas hepáticas - ALT / AST (U/L) /
Glicémia (GL) (g/dl)
Ureia (UR) (mg/dl) / Creatinina (CR) (mmol/L) /
Amilase
Teste de gravidez: Positivo Negativo
Plaquetas
RPR: Positivo Negativo
ESTADIO OMS: Último Estadio []
Outros diagnósticos: Malária Anemia Malnutrição Leucemia Encefalopatia Otite Febre Sarcoma de Kaposi Diarreia Falência Terapeutica

Infecções Oportunistas

Rastreio de ITS(Tem sintomas sugestivos de ITS)?: Sim Não
Rastreio de TB(Tem sintomas sugestivos de TB)?: Sim Não
Resultado para a Investigação para TB de BK e/ou RX?: Positivo Negativo
Tratamento de TB (Veja Cartão de TB): Data Inicio: Data Fim: Sim Não
Profilaxia com Cotrimoxazol - TPC: Data Inicio: Data Fim: Sim Não
Profilaxia com INH - TPI: Data Inicio: Data Fim: Sim Não
Aconselhado para Adesão aos Cuidados: Sim Não

TARV:

Data de Elegibilidade para iniciar o TARV:
Data de Inicio de TARV: [15/dez/2018]
Critério de Elegibilidade para cInicio do TARV:
Data de Reinicio de TARV:
Médicamentos ARVs: Esquema ARV: Tipo: Interrompeu por: Mudança de regime:
Outros Medicamentos
Efeitos Secundarios do Tratamento: Anemia - A Neutropenia - N Pancreatite - P Hepatotoxicidade - H Alterações Psicológicas - AP Neuropatia Periférica - NP Miopatia - M Alergias Cutâneas - AC Lipodistrofia - L Acidose Láctica - AcL Diarreia - D Outros:
Aderente ao TARV: Sim Não
Data da proxima consulta
Data do proximo controlo de CD4:
Referido para outro sector clinico:
Referido para serviços comunitários:
Observacoes:

Annex 3- OpenMRS EPTS Pediatria Seguimento


OpenMRS
Página Inicial | Procurar/Registar Paciente | Dicionário | Cohort Builder | Reporting | Administração
Discard changes | Print
Maria Carlos | PEDIATRIA: SEGUIMENTO (S.TARV: PEDIATRIA SEGUIMENTO) | (Unsaved Form)
FICHA DE SEGUIMENTO PARA PEDIATRIA
REPÚBLICA DE MOÇAMBIQUE
SERVIÇO NACIONAL DE SAÚDE
Mod. SIS - H-10
Nome:Maria Carlos
Data de nascimento: 17/out/2018
Sexo: F
NID: 01080805/17/00010
Nº do livro pré-TARV:
Página do livro pre-TARV:
Linha da Pág do pré-TARV:
Nº do livro TARV:
Página do livro TARV:
Linha da Pág do TARV:
PCR-DNA - 1º Resultado: POS NEG IND Data:
PCR-DNA - 2º Resultado: POS NEG IND Data:
Resultado de teste Rápido de HIV: POS NEG IND Data:
Data da Consulta
Unidade Sanitária
Local Desconhecido
Médico
Idade anos / meses
0 / 0
Peso (kg)
Estatura (cm)
Peso/Estatura (DP) ou IMC (kg/m2) para idade
Classificação Nutricional:
Suplementação/ tratamento Nutricional (ATPU/CSB)
S N Tipo: CSB Plumpy Nut Papa Enriquecida Outro
Desenvolvimento Psico-Motor Adequado para a idade?
S N
Temperatura (ºC):
LABORATÓRIO
Data de Processamento do CD4 (d-m-a)
CD4 (/mm) / CD4 (%)
Carga Viral (CV)
G. Brancos (GB)
Neutrofilos (N) (/mm3 e %)
Linfócitos (L) (/mm3 e %)
Hemoglobina (HgB) (g/dl)
Provas hepáticas - ALT / AST (U/L)
Glicémia (GL) (g/dl)
Ureia (UR) (mg/dl) / Creatinina (CR) (mmol/L)
Amilase
Plaquetas
ESTADIO OMS
Último Estadio []
Outros diagnósticos
Malária Anemia Malnutrição Leucemia Encefalopatia
Otite Febre Sarcoma de Kaposi Diarreia Falência Terapeutica
Infecções Oportunistas
Rastreio de TB(Tem sintomas sugestivos de TB)?
S N
Resultado do BK (POS/NEG)
POS NEG
Tratamento de TB (Veja Cartão de TB):
Data Inicio:
Data Fim:
S N
Profilaxia com Cotrimoxazol - TPC:
Data Inicio:
Data Fim:
S N
Profilaxia com INH - TPI:
Data Inicio:
Data Fim:
S N
Recebeu educação para Adesão aos Cuidados:
S N
TARV:
Data de Elegibilidade para iniciar o TARV:
Data de Inicio de TARV:
[15/dez/2018]
Data de Reinicio de TARV:
Médicamentos ARVs
Esquema ARV:
Tipo:
Interrompeu por:
Mudança de regime:
Outros Medicamentos
Efeitos Secundarios do Tratamento
Anemia - A Neutropenia - N Pancreatite - P
Hepatotoxicidade - H Alterações Psicológicas - AP Neuropatia Periférica - NP
Miopatia - M Alergias Cutâneas - AC Lipodistrofia - L
Acidose Láctica - AcL Diarreia - D Outros:
Aderente ao TARV:
Sim Não
Data da proxima consulta
Data do proximo controlo de CD4:
Referido para outro sector clinico:
Referido para serviços comunitários:
Observacoes:
Submeter